DNA Script vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
DNA Script has raised $335M total including a $165M oversubscribed Series C; received CE Mark in 2025 for SYNTAX System in clinical labs across Europe; developing enzymatic DNA synthesis printers that enable on-demand, benchtop DNA production for.
About
DNA Script is a biotechnology company founded in 2014 and headquartered in Paris, France (with US operations in South San Francisco), that has developed a breakthrough enzymatic DNA synthesis (EDS) platform. Traditional chemical-based DNA synthesis — the process of producing custom DNA sequences used in genomics, synthetic biology, diagnostics, and therapeutic development — relies on hazardous chemicals and generates significant toxic waste. DNA Script's approach replaces these chemicals with enzymes (specifically terminal deoxynucleotidyl transferase, or TdT), enabling faster, greener, and more scalable DNA production at the benchtop.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.